Compare Gold Fields Limited (GFI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs TransMedics Group Inc — how do they compare? Gold Fields Limited trades at $36.83 (market cap $31.87B), while TransMedics Group Inc trades at $77.65 (market cap $2.74B). The key difference: Gold Fields Limited is far larger — about 11.6× TransMedics Group Inc's market cap, and Gold Fields Limited pays a 6% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and TransMedics Group Inc for 24 Days on average.
| GFI | TMDX | |
|---|---|---|
Market Cap | $31.87B | $2.74B |
Volume | 4,169,651 | 949,331 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $150.42 |
52-Week Low | $31.25 | $61.99 |
Typical Hold Time | 49 Days | 24 Days |
Enterprise Value | $32.47B | $3.13B |
Dividend Yield | 6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $36.70, up 4.71% over 24 hours, but technical indicators signal a bearish trend with price near support at $35. The company reported strong 2025 results with revenue of $8.75 billion and net income of $3.57 billion, yielding high profitability margins. However, recent earnings misses and a rejected $27 billion takeover bid for Northern Star have introduced volatility. Analyst consensus remains positive with a $52.75 price target, but the stock faces headwinds from acquisition-related uncertainty and mixed technical signals.
GFI presents a compelling value case with low P/E of 7.3 and robust cash flow growth, but investors must weigh execution risks from its aggressive M&A strategy and recent earnings inconsistencies against its strong fundamentals and shareholder returns. The stock's near-term direction hinges on merger outcomes and gold price stability.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
